The Brincidofovir Oral Suspension, cataloged under National Stock Number 6505-01-735-0149, is classified within Federal Supply Class 6505 (Drugs and Biologicals) of the Medical, Dental, and Veterinary Equipment group. The manufacturer of record is Emergent Biodefense Operations Lansing Llc Dba Emergent Biodefense. The record lists 1 manufacturer part number for this item, enabling identification through both NSN and commercial part number lookups. 3 additional reference documents (drawings, advisory and superseded references) are recorded in the U.S. Government catalog. Current acquisition status: Active. Unit of issue: BT.
| Parameter | Value |
|---|---|
| NSN | 6505-01-735-0149 |
| Primary Part Number | NDC79622-0012-65 |
| Item Name | Brincidofovir Oral Suspension |
| FSC / FSG | 6505 / 65 — Drugs and Biologicals |
| Manufacturer | Emergent Biodefense Operations Lansing Llc Dba Emergent Biodefense |
| Status | ACTIVE |
| Acquisition Status | ACTIVE |
| DEMIL Code | DEMIL A — No Demilitarization Required |
| Hazard | Possible hazard — SDS may be required (DLA HMIC P) |
| Criticality Code | X |
| Unit of Issue | BT |
| Part Number | Manufacturer |
|---|---|
| NDC79622-0012-65 PRIMARY | Emergent Biodefense Operations Lansing Llc Dba Emergent Biodefense (USA) |
| Reference | Meaning |
|---|---|
| 1708843 | 5/1 Secondary reference U.S. Government activity |
| TEMBEXA | 3/1 Design control — primary reference Emergent Biodefense Operations Lansing Llc Dba Emergent Biodefense |
| 6505NCM252104 | 5/1 Secondary reference Defense Medical Standardization Board |
NSN 6505-01-735-0149 is a Brincidofovir Oral Suspension, manufactured by Emergent Biodefense Operations Lansing Llc Dba Emergent Biodefense, classified under FSC 6505, Drugs and Biologicals. Status: active.
NSN 6505-01-735-0149 has 1 manufacturer part number on file: NDC79622-0012-65 (Emergent Biodefense Operations Lansing Llc Dba Emergent Biodefense).
Key specifications for NDC79622-0012-65: Special Features: BRINCIDOFOVIR 10MG/ML ORAL SUSPENSION (TEMBEXA). STORE AT 20 C TO 25 C (68 F TO 77 F); USP CONTROLLED ROOM TEMPERATURE. DISCARD UNUSED PORTION 30 DAYS AFTER FIRST OPENING. PROTECT FROM FREEZING.; Part Name Assigned by Controlling Agency: BRINCIDOFOVIR ORAL SUSPENSION (TEMBEXA). 0 specifications are documented in the U.S. Government catalog.
Possible hazard — SDS may be required (DLA HMIC P). Hazard information on this page is shown exactly as it appears in the DLA record.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-16.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-18.